Free Trial
NASDAQ:VIGL

Vigil Neuroscience Q4 2024 Earnings Report

Vigil Neuroscience logo
$1.71 +0.20 (+13.25%)
Closing price 04:00 PM Eastern
Extended Trading
$1.72 +0.02 (+0.88%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vigil Neuroscience EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Vigil Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vigil Neuroscience Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 12, 2025
Conference Call Time
7:00PM ET

Upcoming Earnings

Vigil Neuroscience's Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vigil Neuroscience Earnings Headlines

William Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Vigil Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vigil Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vigil Neuroscience and other key companies, straight to your email.

About Vigil Neuroscience

Vigil Neuroscience (NASDAQ:VIGL), a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

View Vigil Neuroscience Profile

More Earnings Resources from MarketBeat